{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:09:55Z","timestamp":1791407395343,"version":"4.3.3"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1378\/chest.08-1028","type":"journal-article","created":{"date-parts":[[2008,9,23]],"date-time":"2008-09-23T20:54:34Z","timestamp":1222203274000},"page":"122-129","source":"Crossref","is-referenced-by-count":144,"title":["Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities"],"prefix":"10.1016","volume":"135","author":[{"given":"Michael D.","family":"McGoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaani E.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Oudiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Badesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Galie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Olschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie V.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dufton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrin J.","family":"Despain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.08-1028_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(98)02111-4","article-title":"Primary pulmonary hypertension","volume":"352","author":"Gaine","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.08-1028_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension: results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-1028_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1378\/chest.08-1028_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-1028_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.08-1028_bib6","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.08-1028_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"12 suppl S","key":"10.1378\/chest.08-1028_bib8","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1016\/j.jacc.2004.02.042","article-title":"Endothelin receptor antagonists in pulmonary arterial hypertension","volume":"43","author":"Channick","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.08-1028_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Galie","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.08-1028_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-1028_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-1028_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0168-8278(02)00107-1","article-title":"Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan","volume":"37","author":"Fouassier","year":"2002","journal-title":"J Hepatol"},{"issue":"suppl","key":"10.1378\/chest.08-1028_bib13","first-page":"1","article-title":"Ambrisentan, darusentan, bosentan, and sitaxsentan: differences in inhibition of hepatobilliary transporters in two species [abstract]","volume":"39","author":"Brouwer","year":"2007","journal-title":"Drug Metab Rev"},{"key":"10.1378\/chest.08-1028_bib14","first-page":"A728","article-title":"Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension. Results of the ARIES-2 Study","volume":"3","author":"Olschewski","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1378\/chest.08-1028_bib15","doi-asserted-by":"crossref","first-page":"121S","DOI":"10.1378\/chest.130.4_MeetingAbstracts.121S-a","article-title":"ARIES-1: A placebo-controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension","volume":"130","author":"Oudiz","year":"2006","journal-title":"Chest"},{"key":"10.1378\/chest.08-1028_bib16","first-page":"A512","article-title":"Background incidence of elevated liver aminotransferases in pulmonary arterial hypertension (PAH): results from 4 placebo-controlled trials","volume":"3","author":"Abbott","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1378\/chest.08-1028_bib17","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT)","volume":"106","author":"Luscher","year":"2002","journal-title":"Circulation"},{"issue":"7 pt 1","key":"10.1378\/chest.08-1028_bib18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0895-7061(02)02933-3","article-title":"Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension","volume":"15","author":"Nakov","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1378\/chest.08-1028_bib19","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"10.1378\/chest.08-1028_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":"Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial","volume":"21","author":"Carducci","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369209600763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369209600763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T08:24:30Z","timestamp":1545726270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369209600763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0012369209600763"],"URL":"https:\/\/doi.org\/10.1378\/chest.08-1028","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}